Skip to main content

Table 1 Patient Characteristics before and after Surgery (n = 119)

From: Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months

Characteristics No.(%) Characteristics No.(%)
Clinical stage   Grade  
   II B 32 (26.9%)    I 1 (0.8%)
   III A 56 (47.1%)    II 67 (56.3%)
   III B 22 (18.5%)    III 15 (12.6%)
   III C 9 (7.5%)    Not graded 36 (30.3%)
Pre-cALN   Post-cALN  
   negative 36 (30.3%)    negative 81 (68.1%)
   positive 83 (69.7%)    positive 38 (31.9%)
Pre-ER   Post-ER※  
   negative 58 (48.7%)    negative 82 (75.2%)
   positive 61 (51.3%)    positive 27 (24.8%)
Pre-PR   Post-PR※  
   negative 60 (50.4%)    negative 84 (77.1%)
   positive 59 (49.6%)    positive 25 (22.9%)
Pre-HER-2   Post-HER-2※  
   0-2+ 86 (72.3%)    0-2+ 79 (72.5%)
   3+ 33 (27.7%)    3+ 30 (27.5%)
Pre-Ki67   Post-Ki67※  
   ≤ 20% 74 (62.2%)    ≤ 20% 93 (85.3%)
   >20% 45 (37.8%)    >20% 16 (14.7%)
Pathology   Pathological tumor size  
   IDC 92 (77.3%)    ≤ 2 cm 28 (23.5%)
   ILC 4 (3.4%)    > 2 cm 59 (49.6%)
   other 23 (19.3%)    unmeasured 32 (26.9%)
Clinical response   pALN  
   CR 27 (22.7%)    N 0 39 (32.8%)
   PR 78 (65.6%)    N 1-3 24 (20.2%)
   SD 13 (10.9%)    N 4-9 35 (29.4%)
   PD 1 (0.8%)    N >9 21 (17.6%)
Pathological response in tumor site    
   T-A 22 (18.5%)   
   T-B 75 (63.0%)   
   T-C 22 (18.5%)   
  1. Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.
  2. ※109 patients were evaluated after neoadjuvant chemotherapy, because of 10 patients with no residual tumor in postoperative tissue.